Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer EF, Schmitt WD, Hanusch C, Fasching PA, Lübbe K, Solbach C, Huober J, Rhiem K, Marmé F, Reimer T, Schmidt M, Sinn BV, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Loibl S. Denkert C, et al. Among authors: schmidt m. Lancet Oncol. 2021 Aug;22(8):1151-1161. doi: 10.1016/S1470-2045(21)00301-6. Epub 2021 Jul 9. Lancet Oncol. 2021. PMID: 34252375
Prognostic impact of haemoglobin levels in breast cancer.
Boehm DU, Lebrecht A, Schmidt M, Siggelkow W, Lindner C, Litz A, Ulbrich E, Koelbl H. Boehm DU, et al. Among authors: schmidt m. Anticancer Res. 2007 Mar-Apr;27(2):1223-6. Anticancer Res. 2007. PMID: 17465267 Free article.
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S. von Minckwitz G, et al. Among authors: schmidt m. J Clin Oncol. 2009 Apr 20;27(12):1999-2006. doi: 10.1200/JCO.2008.19.6618. Epub 2009 Mar 16. J Clin Oncol. 2009. PMID: 19289619 Clinical Trial.
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Schroth W, et al. Among authors: schmidt m. JAMA. 2009 Oct 7;302(13):1429-36. doi: 10.1001/jama.2009.1420. JAMA. 2009. PMID: 19809024 Free PMC article.
Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.
Müller V, Thomssen C, Schmidt M, Glados M, Jackisch C, Heilmann V, Hinke A, Lehnert A, Borowicz H, Möbus V. Müller V, et al. Among authors: schmidt m. BMC Cancer. 2010 Aug 16;10:430. doi: 10.1186/1471-2407-10-430. BMC Cancer. 2010. PMID: 20712886 Free PMC article. Clinical Trial.
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M. Karn T, et al. Among authors: schmidt m. Eur J Cancer. 2012 Jan;48(1):12-23. doi: 10.1016/j.ejca.2011.06.025. Epub 2011 Jul 7. Eur J Cancer. 2012. PMID: 21741824
10,250 results
You have reached the last available page of results. Please see the User Guide for more information.